ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effectiveness, safety, and treatment patterns of GLP-1 receptor agonists in adolescents with obesity: a multicenter retrospective study from Saudi Arabia.Frontiers in nutrition · 2026Article
- Community Pharmacists' Knowledge and Counseling Competence on GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes Care in Türkiye: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease.Pharmaceuticals (Basel, Switzerland) · 2025Article
- ApoB Testing in Dyslipidemia Management: Knowledge and Practices of Healthcare Providers in Saudi Arabia.Journal of multidisciplinary healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors represent major advancements in the management of type 2 diabetes. However, many patients remain suboptimally managed with these therapies. This underutilization highlights the need for practical implementation strategies in real-world settings. Community pharmacists can play a crucial role in integrating these therapies into diabetes care. This study aimed to evaluate community pharmacists' knowledge, counseling practices, perceived barriers, and clinical decision-making regarding these therapies. Methods: A cross-sectional, questionnaire-based survey was conducted among licensed community pharmacists in the Qassim region, Saudi Arabia. Results: A total of 211 community pharmacists participated in this study. Of these, 83.4% were male and 16.6% were female. The participants' perceived levels of knowledge of the pharmacology and basic concepts of GLP-1 receptor agonists and SGLT-2 inhibitors were high, with mean scores (± SD) of 13.41 ± 2.43 and 13.36 ± 2.59, respectively, out of a maximum of 16. However, knowledge related to clinical therapeutics and evidence-based decision-making was low, with only 24.2%, 23.7%, and 32.2% of the participants correctly answering the three patient-based case scenarios. Many participants counseled and discussed these therapies in patients with type 2 diabetes. However, the participants reported several barriers, including high medication costs (67.3%), concerns about side effects (33.2%), challenges with patient adherence (28.4%), and limited time to engage in discussions with patients (22.7%). Notably, 88.2% of the participants indicated that continuing professional development in diabetes therapy is required. Conclusion: Many participants had substantial gaps in their applied knowledge of clinical therapeutics and persistent barriers to clinical engagement remained. Targeted educational strategies and system-level support are crucial for enhancing the role of community pharmacists in managing type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.